The Phage Raises ¥570 Million to Predict Postprandial Blood Glucose Fluctuations with AI—Forms Capital and Business Alliance with Tokio Marine

The Phage, which is engaged in the research and development of the blood glucose foundation model “CGFM” that learns continuous blood glucose data, announced on the 9th that it has raised a total of ¥570 million through a Series A 1st round third-party allotment and loans. Read more. The round was led by Itochu Technology Ventures, with Tokio Marine & Nichido Fire Insurance and Fukui Capital Partners joining as new shareholders. Genesia Ventures and Vision Incubate, who led the previous two fund

NewsBeagle is a discovery engine. We show the headline, a short source-supplied summary and clear attribution. The complete reporting remains with the publisher.